Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

Table 3 Targeting agents on the efficacy of CSCs associated surface markers in clinical trials

Antibody target	Drug name	Solid Tumor	Phase	Enrollment	NCT number	Current status
CD47	TTI-621	Solid tumor	I	260	NCT02663518	Recruiting
	Hu5F9-G4	Solid tumor	I	88	NCT02216409	Completed
	IBI188	Advanced malignancies	I	42	NCT03763149	Recruiting
	AO-176	Solid tumor	I	90	NCT03834948	Recruiting
	SRF231	Solid tumor	I	148	NCT03512340	Recruiting
	Bivatuzumab mertansine	Metastatic breast cancer	I	24	NCT02254005	Completed
CD44	RO5429083	Malignant solid tumors	I	65	NCT01358903	Completed
CD44	SPL-108	Ovarian cancer	I	18	NCT03078400	Recruiting
PD-1	Nivolumab	Glioblastoma multiforme	II	29	NCT02550249	Completed
	Pembrolizumab	Glioblastoma multiforme	II	80	NCT02337491	Completed
	Durvalumab	Solid tumors	II	124	NCT02403271	Completed
PD-L1	Atezolizumab	Non-small-cell lung cancer	III	1225	NCT02008227	Completed
PD-L1	Avelumab	Recurrent glioblastoma	II	52	NCT03291314	Completed
TIM3	Sym023	Solid tumors	I	48	NCT03489343	Recruiting
CD70	Varlilumab (CDX-1127)	Solid tumors	II	175	NCT02335918	Completed
LAG3	Sym022	Solid tumors	I	30	NCT03489369	Recruiting
CD70/LAG3	MGD013	Solid tumors	I	255	NCT03219268	Recruiting
EpCAM/CD3	Catumaxomabr (emovab)	Ovarian cancer	II	44	NCT00189345	Completed
CD44V6	AMC303	Solid tumor	I	55	NCT03009214	Recruiting
CTLA-4	Ipilimumab	Non-small-cell lung cancer	II	24	NCT01820754	Completed

ISSN: 1476-4598